Inline/Instant Measurement for PhArma eXtrusion
Ended · Germany
Source: EU Funding & Tenders Portal
Most pharma companies still rely on the age old batch manufacturing method and today the European Pharma industry faces the major challenge of strong competition from lower cost manufacturers. The trend is disinvestment in Europe or alternatively investment in innovative manufacturing technologies and more advanced and targeted pharmacological products. Batch manufacturing implies inflexibility, h
- Status
- Closed
- Sector
- Manufacturing (Industrial), Education
- Location
- Germany
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Inline/Instant Measurement for PhArma eXtrusion
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Most pharma companies still rely on the age old batch manufacturing method and today the European Pharma industry faces the major challenge of strong competition from lower cost manufacturers. The trend is disinvestment in Europe or alternatively investment in innovative manufacturing technologies and more advanced and targeted pharmacological products. Batch manufacturing implies inflexibility, high costs and poor biological delivery of more advanced new drugs. New techniques like Continuous Manufacturing, extruder based Hot Melt Extrusion and Wet Granulation are the future, allowing for automation, improved efficiency, and proper bioavailability for poorly soluble molecules. Safety and fulfilment of their potential mean these new processes require much more advanced Process Analytical Technology than is currently available. ColVisTec will extend its unique UV-VIS platform to incorporate NIR and Raman. IMPAX represents the first production monitoring platform to combine three spectra (UV-VIS, NIR and Raman) and will provide extensive, real time, spectroscopy measurements adapted to the extruder environment with pharma software compliant with EMA and FDA regulations. The initial markets will be Europe and the USA, where ColVisTec is already active. IMPAX users like pharma companies, contract manufacturers and universities will benefit from access to lower cost production and an innovative solution for drug delivery. Important pharma stakeholders (AbbVie, Endcap, FCNW, Catalent, BASF and Reutlingen University) have already shown their interest and support in written form and undertaken to test the new IMPAX platform at their facilities. IMPAX will contribute to Europe’s pharma industry adopting “Industry 4.0” digitalisation and automation principles and will facilitate the European market shift towards CM and PAT techniques boosting the uptake of more competitive manufacturing technologies. |
Location
Country | Germany |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Education |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Manufacturing (Industrial) projects in Germany
- Veja Mate Offshore Wind Farm Project
- Albatros Offshore Wind Farm North Sea Germany
- Hohe See Offshore Wind Farm North Sea Germany
- EnBW Baltic 2 Offshore Wind Farm
- Herdecke 400MW CCGT GasFired Power Plant Grenada
- Global Tech I Offshore Wind Farm
- Nordsee One Offshore Wind Project North Sea
- Westfalen Power Plant Units D and E Hamm
